Jazz is suing Teva, Apotex, Alkem and a few other generic drugmakers for alleged infringement on the cannabis-derived therapy, the company said in a Securities and Exchange Commission filing. The drug won its FDA approval back in 2018 as the first therapy comprised of an active ingredient derived from marijuana.
As for Epidiolex, the drug is on a growth streak, generating nearly $530 million in the first 9 months of 2022.